Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04436081 · ClinicalTrials.gov registry record · Phase 2

Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

A Phase 2 study, sponsored by Eastern Virginia Medical School.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target

NCT04436081 is a Phase 2 study that is actively recruiting participants, run by Eastern Virginia Medical School. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04436081, a Phase 2 study, is actively recruiting participants, sponsored by Eastern Virginia Medical School.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to 1) determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants and 2) determine whether THC-free CBD oil can reduce the burden on caregivers and increase the participants' quality of life.

Interventions

  • DRUG Placebo
  • DRUG THC-free CBD Oil

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-02-26
Est. Completion 2024-03
Phase Phase 2

Sponsor

Eastern Virginia Medical School

36 total trials

What the Registry Record Tells You About NCT04436081

The ClinicalTrials.gov registry entry for NCT04436081 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Virginia Medical School, which has 36 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04436081 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04436081 about?

NCT04436081 is a clinical study titled "Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease". This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to 1) determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants and 2) determine whether THC-free CBD oil can reduce the burden on caregivers and increase the p...

What is the current status of trial NCT04436081?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-02-26. Estimated completion is 2024-03.

What interventions are being tested in trial NCT04436081?

The interventions under investigation include: Placebo (DRUG), THC-free CBD Oil (DRUG).

Who is sponsoring clinical trial NCT04436081?

This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.